FY2025 EPS Estimates for XOMA Royalty Reduced by Analyst

by · The Cerbat Gem

XOMA Royalty Corporation (NASDAQ:XOMA – Free Report) – Analysts at HC Wainwright lowered their FY2025 earnings per share estimates for XOMA Royalty in a research report issued to clients and investors on Thursday, December 11th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will earn $0.51 per share for the year, down from their prior estimate of $1.17. HC Wainwright currently has a “Buy” rating and a $97.00 target price on the stock. The consensus estimate for XOMA Royalty’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA Royalty’s Q4 2025 earnings at $0.05 EPS and FY2026 earnings at $0.61 EPS.

XOMA Royalty (NASDAQ:XOMA – Get Free Report) last released its quarterly earnings data on Wednesday, November 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.33). The business had revenue of $9.35 million during the quarter, compared to analyst estimates of $11.47 million. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%.

A number of other analysts also recently commented on the stock. Wall Street Zen downgraded shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Zacks Research lowered shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 18th. UBS Group set a $76.00 target price on shares of XOMA Royalty in a research note on Tuesday, December 9th. Leerink Partners cut their price target on shares of XOMA Royalty from $58.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 8th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, XOMA Royalty has a consensus rating of “Hold” and an average price target of $60.60.

Get Our Latest Research Report on XOMA Royalty

XOMA Royalty Price Performance

XOMA stock opened at $25.49 on Monday. The business has a 50 day simple moving average of $33.09 and a 200-day simple moving average of $31.06. XOMA Royalty has a twelve month low of $18.35 and a twelve month high of $39.92. The company has a market capitalization of $315.57 million, a P/E ratio of 34.45 and a beta of 0.94. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07.

Insider Buying and Selling at XOMA Royalty

In other XOMA Royalty news, CEO Owen Hughes purchased 100,000 shares of XOMA Royalty stock in a transaction that occurred on Thursday, December 4th. The stock was acquired at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the transaction, the chief executive officer owned 102,000 shares in the company, valued at $2,555,100. This trade represents a 5,000.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas M. Burns sold 4,330 shares of the stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $35.99, for a total value of $155,836.70. Following the transaction, the chief financial officer directly owned 30,079 shares of the company’s stock, valued at approximately $1,082,543.21. This trade represents a 12.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 7.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of XOMA. Vanguard Group Inc. lifted its stake in XOMA Royalty by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after purchasing an additional 29,298 shares in the last quarter. Opaleye Management Inc. grew its stake in XOMA Royalty by 0.8% during the 2nd quarter. Opaleye Management Inc. now owns 255,087 shares of the biotechnology company’s stock worth $6,428,000 after buying an additional 2,044 shares during the last quarter. Woodline Partners LP grew its holdings in shares of XOMA Royalty by 16.5% during the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after buying an additional 29,715 shares during the last quarter. Geode Capital Management LLC boosted its position in XOMA Royalty by 9.1% in the second quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after buying an additional 16,929 shares during the last quarter. Finally, Stonepine Capital Management LLC grew its holdings in XOMA Royalty by 17.2% during the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after acquiring an additional 22,330 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

(Get Free Report)

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.

Featured Stories